We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$610M
1-Year Est. Return
40.86%
This Fund
S&P 500
This Quarter
Est. Return
+14.04%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$229M
AUM Growth
+$34.9M
(+18%)
Cap. Flow
+$13.6M
Cap. Flow
% of AUM
5.94%
Top 10 Holdings %
Top 10 Hldgs %
57.76%
Holding
47
New
12
Increased
9
Reduced
17
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$14.1M |
| 2 |
Cigna
CI
|
+$11.8M |
| 3 |
UroGen Pharma
URGN
|
+$6.62M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
+$6.05M |
| 5 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$4.75M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$8.21M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$6.42M |
| 3 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$5.77M |
| 4 |
HNGR
Hanger Inc.
HNGR
|
+$5.07M |
| 5 |
Viking Therapeutics
VKTX
|
+$4.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.63% |
| 2 | Technology | 3.03% |
| 3 | Industrials | 1.92% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
AC Immune
ACIU
$227M
| $3.59M | 1.57% |
+710,541
| New | +$4.52M |
|
|
TLGT
27
DELISTED
Teligent, Inc
TLGT
| $3.53M | 1.54% |
304,157
-50,604
| -14% | -$763K |
|
|
MODV
28
DELISTED
ModivCare
MODV
| $3.49M | 1.53% |
52,324
-25,974
| -33% | -$1.7M |
|
29
Kura Oncology
KURA
$922M
| $2.87M | 1.25% |
172,894
-143,687
| -45% | -$2.21M |
|
30
MacroGenics
MGNX
$235M
| $1.93M | 0.85% |
107,560
-86,569
| -45% | -$1.5M |
|
|
MTEM
31
DELISTED
Molecular Templates, Inc.
MTEM
| $1.73M | 0.76% |
+19,853
| New | +$1.46M |
|
32
MeiraGTx Holdings
MGTX
$1.09B
| $1.57M | 0.69% |
+91,317
| New | +$1.29M |
|
33
CALL
Aldeyra Therapeutics
ALDX
$91.7M
| $1.47M | 0.64% |
+162,300
| New | +$1.38M |
|
|
UROV
34
DELISTED
Urovant Sciences Ltd.
UROV
| $1M | 0.44% |
+99,870
| New | +$1.02M |
|
35
Avalo Therapeutics
AVTX
$976M
| $665K | 0.29% |
40
-67
| -63% | -$1M |
|
|
CDTX
36
DELISTED
Cidara Therapeutics
CDTX
| $584K | 0.26% |
11,013
-1,275
| -10% | -$69.9K |
|
37
Neurogene
NGNE
$696M
| $76K | 0.03% |
1,415
-2,599
| -65% | -$131K |
|
38
Enanta Pharmaceuticals
ENTA
$372M
| $68K | 0.03% |
+709
| New | +$63.6K |
|
39
Axogen
AXGN
$2.1B
| – | – |
-209,088
| Closed | -$4.27M |
|
40
Evolus
EOLS
$394M
| – | – |
-195,911
| Closed | -$2.33M |
|
|
LKFT
41
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
| – | – |
-62,850
| Closed | -$5.77M |
|
42
Ligand Pharmaceuticals
LGND
$6.02B
| – | – |
-20,198
| Closed | -$1.71M |
|
|
OPTN
43
DELISTED
OptiNose
OPTN
| – | – |
-9,354
| Closed | -$870K |
|
|
44
Viking Therapeutics
VKTX
$4.04B
| – | – |
-624,000
| Closed | -$4.77M |
|
|
PVLA
45
Palvella Therapeutics
PVLA
$1.98B
| – | – |
-4,161
| Closed | -$885K |
|
|
GTS
46
DELISTED
Triple-S Management Corporation
GTS
| – | – |
-68,863
| Closed | -$1.14M |
|
|
AGN
47
DELISTED
Allergan plc
AGN
| – | – |
-61,400
| Closed | -$8.21M |
|
Similar funds
PL
BFC
DCM
SAM
CBB
AIG
FFWA
CIP
Prosight Management's Q1 2019 Portfolio in Review
As of Q1 2019, Prosight Management held 47 positions worth $229M, up 18% from $194M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Prosight Management deployed $13.6M of net new capital in Q1 2019, opening 12 new positions and adding to 9 existing holdings. Its largest new stake was Bristol-Myers Squibb: 283,000 shares worth $13.5M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 91% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $6.42M trimmed.
- Prosight Management's largest Q1 2019 buy was Bristol-Myers Squibb: 283,000 shares worth $13.5M.
- Prosight Management added most to Cigna in Q1 2019, an estimated $11.8M increase.
- Prosight Management's biggest Q1 2019 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $6.42M.
- Prosight Management fully exited Allergan plc in Q1 2019, selling an estimated $8.21M.
- Prosight Management's ten largest holdings make up 58% of its $229M portfolio in Q1 2019.
- Prosight Management opened 12 new positions and closed 9 in Q1 2019.
- Prosight Management's portfolio value rose 18% quarter-over-quarter to $229M.
Based on Prosight Management's 13F filing for Q1 2019, filed 15 May 2019.